Seroatlas · Human Serome Atlas

SCRT2

Transcriptional repressor scratch 2

Also known as: SCRT2_HUMAN, ZNF898B

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q9NQ03
Gene: SCRT2
Ensembl: ENSG00000215397
Chromosome: 20
Canonical length: 307 aa
Protein class: Predicted intracellular proteins, Transcription factors
Subcellular location: Nucleoplasm

OverviewNCBI Gene

Enables sequence-specific double-stranded DNA binding activity. Predicted to be involved in negative regulation of extrinsic apoptotic signaling pathway via death domain receptors and negative regulation of transcription by RNA polymerase II. Predicted to act upstream of or within regulation of neuron migration. Predicted to be located in chromatin. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

307 residues, UniProt reviewed canonical sequence.

>Q9NQ03|SCRT2
     1  MPRSFLVKKI KGDGFQCSGV PAPTYHPLET AYVLPGARGP PGDNGYAPHR LPPSSYDADQ
    61  KPGLELAPAE PAYPPAAPEE YSDPESPQSS LSARYFRGEA AVTDSYSMDA FFISDGRSRR
   121  RRGGGGGDAG GSGDAGGAGG RAGRAGAQAG GGHRHACAEC GKTYATSSNL SRHKQTHRSL
   181  DSQLARKCPT CGKAYVSMPA LAMHLLTHNL RHKCGVCGKA FSRPWLLQGH MRSHTGEKPF
   241  GCAHCGKAFA DRSNLRAHMQ THSAFKHYRC RQCDKSFALK SYLHKHCEAA CAKAAEPPPP
   301  TPAGPAS

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against SCRT2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.57
Highest tissue expression: 3.9 nTPM

Expression across tissuesHPA

Tissue

cerebellum: 3.9 nTPM
retina: 3.6 nTPM
cerebral cortex: 1.9 nTPM
midbrain: 0.5 nTPM
spinal cord: 0.4 nTPM
amygdala: 0.2 nTPM

Single-cell type

brain inhibitory neurons: 0.9 nCPM
brain excitatory neurons: 0.6 nCPM
astrocytes: 0.1 nCPM
oligodendrocyte progenitor cells: 0.1 nCPM
oligodendrocytes: 0.1 nCPM
other brain neurons: 0.1 nCPM

Immune cell

neutrophil: 0.2 nTPM
basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM

Brain region

cerebral cortex: 20 nTPM
cerebellum: 16 nTPM
thalamus: 13 nTPM
medulla oblongata: 12 nTPM
pons: 9 nTPM
white matter: 7.8 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.39
gnomAD pLI: 0.91
gnomAD missense Z: 2.59
DepMap mean gene effect: 0.06
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads SCRT2 as an antibody target. Whether an autoantibody or antibody against SCRT2 could matter depends on whether native SCRT2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

SCRT2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label SCRT2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...